Table 1 The catalog of drugs in the optimized personalized combinatorial therapies

c

1

2

3

3

3

3

3

Embelin

0.7

5.9

31.5

2

13

lung: small_cell_carcinoma,TP53:wt

XIAP

Nutlin-3a

4.1

8.0

24.5

2

11

TP53:wt,RB1:wt

MDM2

Bicalutamide

1.3

3.9

21.4

2

11

ALK:wt,KRAS:0

Androgen receptor (ANDR)

XMD8-85

1.0

5.7

19.5

2

9

CDKN2A:wt,malignant_melanoma

ERK5 (MK07)

Shikonin

1.7

1.7

11.8

1

2

TP53:wt

unknown

NVP-BEZ235

0.6

-

8.0

2

4

PTEN:wt,EZH2:wt

PI3K (Class 1) and mTORC1/2

CI-1040

1.8

3.8

7.6

2

6

malignant_melanoma,TP53:p.R273H

MEK1/2

EHT 1864

1.1

3.5

7.1

1

2

lung: small_cell_carcinoma

Rac GTPases

BMS-754807

-

4.1

7.0

2

14

neuroblastoma,KRAS:p.G12V

IGF1R

PLX4720

0.8

3.5

6.9

2

13

BRAF:p.V600E,MSH2:wt

BRAF

BX-795

0.7

5.7

6.3

2

14

glioma,KRAS:+

TBK1, PDK1, IKK, AURKB/C

AKT inhibitor VIII

2.4

5.6

6.3

2

9

lung: NSCLC: adenocarcinoma,EGFR:wt

AKT1/2

AZD6482

3.8

6.2

6.3

1

2

glioma

PI3Kb (P3C2B)

RDEA119

3.9

7.4

6.0

2

13

malignant_melanoma,BRCA1:0

MEK1/2

MS-275

4.9

5.9

5.9

2

6

lung: small_cell_carcinoma,RB1:wt

HDAC

BI-D1870

0.7

1.7

5.3

2

14

CCND1:0,MYCN:0

RSK1/2/3/5, PLK1, AURKB

MG-132

1.4

-

5.2

1

2

glioma

Proteasome

FH535

1.5

3.6

5.0

2

14

breast,CCND1:+

unknown

Docetaxel

2.8

1.3

4.6

2

9

upper_aerodigestive_tract,EGFR:wt

Microtubules

CGP-60474

-

2.8

4.3

1

2

CDKN2a(p14):p.?

CDK1/2/5/7/9

AS601245

1.7

2.5

4.2

2

7

ovary,osteosarcoma

JNK

NVP-TAE684

1.5

3.8

4.2

1

1

APC:wt,stomach

ALK

Epothilone B

1.3

1.4

4.1

2

7

PIK3CA:p.E545K,TP53:p.R248W

Microtubules

Camptothecin

2.9

3.8

4.1

2

7

AML,lymphoblastic T cell leukaemia

TOP1

Vorinostat

4.1

5.7

4.1

1

2

MYCN:+

HDAC inhibitor Class I, IIa, IIb, IV

A-443654

1.4

3.6

4.1

1

1

SMAD4:wt

AKT1/2/3

PD-0325901

1.1

2.1

3.9

2

11

large_intestine,VHL:0

MEK1/2

RO-3306

1.5

3.2

3.9

2

11

cervix,MYCL1:0

CDK1

17-AAG

2.2

2.2

3.8

2

6

STK11:wt,MET:0

HSP90

S-Trityl-L-cysteine

1.1

3.5

3.8

1

1

FBXW7:wt

KIF11

ZM-447439

0.1

1.3

3.6

2

7

lung: NSCLC: large cell,RB1:-

AURKB

Vinblastine

1.4

2.2

3.2

2

13

upper_aerodigestive_tract,IDH1:0

Microtubules

Paclitaxel

0.1

2.5

3.2

2

11

oesophagus,TSC1:wt

Microtubules

AICAR

0.6

1.7

2.9

1

1

KDM6A:wt

AMPK agonist

BIBW2992

1.4

2.2

2.9

1

1

ERBB2:0

EGFR, ERBB2

JNK-9L

-

-

2.7

1

2

AML

JNK

BAY 61-3606

1.0

2.1

2.7

1

2

Ewings sarcoma

SYK

AMG-706

-

-

2.7

1

2

Ewings sarcoma

VEGFR, RET, c-KIT, PDGFR

AZ628

-

2.2

2.5

2

9

KRAS:p.G12D,FGFR3:0

BRAF

BMS-536924

-

1.1

2.5

2

7

KRAS:+,MDM2:+

IGF1R

JW-7-52-1

1.1

1.7

2.5

1

2

stomach

MTOR

Elesclomol

1.0

3.5

2.4

2

8

bladder,TSC1:wt

HSP70

Pyrimethamine

0.8

3.5

2.4

1

2

pancreas

Dihydrofolate reductase (DHFR)

KIN001-135

0.3

0.7

2.2

1

1

MET:+

IKKE

Dasatinib

-

-

2.0

2

13

Renal cell carcinoma,NRAS:0

ABL, SRC, KIT, PDGFR

ABT-888

1.5

2.5

1.7

2

11

lymphoid_neoplasm other,CDK4:0

PARP1/2

BI-2536

2.9

3.1

1.7

2

2

CDKN2A:p.0?,MYC:0

PLK1/2/3

IPA-3

-

-

1.7

1

2

B cell lymphoma

PAK

WO2009093972

1.5

2.0

1.7

1

2

soft tissue other

PI3Kb

Methotrexate

1.7

4.2

1.5

2

8

lymphoblastic leukemia,GNAS:wt

Dihydrofolate reductase (DHFR)

Roscovitine

0.1

3.1

1.5

1

2

Burkitt lymphoma

CDKs

FTI-277

1.4

1.4

1.5

1

2

thyroid

Farnesyl transferase (FNTA)

PAC-1

1.5

1.5

1.5

1

2

Burkitt lymphoma

CASP3 activator

CCT018159

1.3

3.5

1.4

2

14

osteosarcoma,PTEN:0

HSP90

PF-4708671

0.7

0.8

1.4

2

13

Myeloma,BRCA1:wt

p70 S6KA

TW 37

0.8

1.1

1.4

2

6

MLH1:wt,APC:0

BCL-2, BCL-XL

MK-2206

1.3

1.4

1.4

1

2

endometrium

AKT1/2

JNK Inhibitor VIII

-

-

0.3

1

2

AML

JNK

Obatoclax Mesylate

-

-

0.1

2

2

RB1:-,CDK6:+

BCL-2, BCL-XL, MCL-1